68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2024

Conditions
Tumor, Solid
Interventions
DIAGNOSTIC_TEST

68Ga-FAPI-46 PET Scan

68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.

Trial Locations (1)

45147

Department of Nuclear medicine, University hospital Essen, Essen

All Listed Sponsors
lead

University Hospital, Essen

OTHER

NCT05160051 - 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer | Biotech Hunter | Biotech Hunter